
commerci anim health
vaccin product also provid product
servic relat biodevic diagnost
tool genet
requir disclosur end report
number thesi evolv bit
innov keep us interest buy weak pt
view current cl king meet event calendar coverag univers
zoeti post good beat our/street estim top
bottom line although left guidanc intact although think next
apoquel leg-up last buy rate stay intact core thesi
zoeti grow revenu via exist companion product
maintain stabl perform livestock busi drive
earn growth effici initi base stabl strong
cash flow dividend share repurchas view stabl long-
term grower attract market reiter buy rate lower
pt
take financi strong quarter commentari around
competit revolut rimadyl well lack blow-out number
dermatolog simparica like spook investor yesterday lead
sell-off revolut rimadyl pressur isnt anyth new
season slow flea/tick sale like dermatolog core product
growth remain intact type pullback exactli time buy
rare sale asset
simparica
drive alpha thesi evolv year-over-year
dermatolog arent outsid season norm see diminish alpha
opportun above-market peak sale expect next wave stock
appreci like come commentari around innov pain
parasiticid comment earli meantim
look exist product drive next year growth
revenu ep zoeti post revenu vs
our/th street compar
quarter last year beat driven strong sale companion anim
currenc adjust ep beat street
outlook despit beat zoeti maintain revenu guidanc
midpoint respect ep
adjust ep guidanc compani post
beat last year well didnt updat guidanc either think
zoeti simpli prefer wiggl room
dermatolog updat dermatolog portfolio apoquel
cytopoint sale growth flat
sequenti last two quarter
dermatolog connect allergi would expect strength
spring summer month although zoeti
maintain languag peak sale think could
like
flea tick merck nr eli lilli nr announc
strong result flea tick medic although think oral flea
tick grow categori prior topic use medic think frontlin
look like competit market zoeti note simparica revenu
year year product record although
signific stock sens peak sale simparica
like
pipelin nexvet portfolio provid upsid number although
drug acquir portfolio slate late
believ compani work biolog would pain product
dog cat type product could gener revenu excess
apoquel recal apoquel alreadi regard one
top anim health drug time pain market roughli
safer biolog chronic use would grow categori significantli sure
zoeti late stage work flea tick heartworm combo
drug compani first market type drug could
displac even top-sel drug market
model decreas respect revenu estim
increas adjust ep forecast fine-tun
adjust ep estim increas
ep number reflect beat rel us
price target price round price-to-earnings
multipl vs previous revis adjust ep estim
risk achiev price target
price concess competit
strong growth prospect outsid
page
